- Home
- ABSI vs ETON Comparison
ABSI vs ETON Comparison
Compare ABSI & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABSI
- ETON
- Stock Information
- Founded
- ABSI 2011
- ETON 2017
- Country
- ABSI United States
- ETON United States
- Employees
- ABSI N/A
- ETON N/A
- Industry
- ABSI Biotechnology: Pharmaceutical Preparations
- ETON Biotechnology: Pharmaceutical Preparations
- Sector
- ABSI Health Care
- ETON Health Care
- Exchange
- ABSI Nasdaq
- ETON Nasdaq
- Market Cap
- ABSI 353.8M
- ETON 329.8M
- IPO Year
- ABSI 2021
- ETON 2018
- Fundamental
- Price
- ABSI $3.01
- ETON $14.22
- Analyst Decision
- ABSI Strong Buy
- ETON Strong Buy
- Analyst Count
- ABSI 6
- ETON 3
- Target Price
- ABSI $7.83
- ETON $27.67
- AVG Volume (30 Days)
- ABSI 4.4M
- ETON 248.9K
- Earning Date
- ABSI 03-18-2025
- ETON 03-18-2025
- Dividend Yield
- ABSI N/A
- ETON N/A
- EPS Growth
- ABSI N/A
- ETON N/A
- EPS
- ABSI N/A
- ETON N/A
- Revenue
- ABSI $4,534,000.00
- ETON $39,011,000.00
- Revenue This Year
- ABSI $257.06
- ETON $107.69
- Revenue Next Year
- ABSI $112.29
- ETON $65.50
- P/E Ratio
- ABSI N/A
- ETON N/A
- Revenue Growth
- ABSI N/A
- ETON 23.29
- 52 Week Low
- ABSI $2.45
- ETON $3.03
- 52 Week High
- ABSI $6.72
- ETON $18.41
- Technical
- Relative Strength Index (RSI)
- ABSI 38.78
- ETON 43.84
- Support Level
- ABSI $2.81
- ETON $12.73
- Resistance Level
- ABSI $3.15
- ETON $15.73
- Average True Range (ATR)
- ABSI 0.23
- ETON 0.93
- MACD
- ABSI -0.02
- ETON -0.01
- Stochastic Oscillator
- ABSI 33.61
- ETON 49.67
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.